Roche Advances Enicepatide and Petrelintide Into Phase III While Initiating Combination Trial at ADA 2026

Simultaneous Phase III advancement of two investigational obesity assets, combined with a mid-2026 combination trial initiation, signals that Roche is building toward a manufacturing and CMC regulatory workload that GLP-1-class biologic programs rarely compress into a single cycle. The company will present late-breaking Phase II data on both enicepatide (CT-388) and petrelintide at the American Diabetes Association's 2026 Scientific Sessions, 5–8 June in Chicago.

Enicepatide, a dual GLP-1/GIP receptor agonist, generated 48-week weight-loss outcomes from the Phase II CT388-103 study that Roche characterises as clinically meaningful across a broad overweight and obese population. A parallel Phase II study, CT388-104, is evaluating the same asset in participants with comorbid type 2 diabetes, extending the dataset that will underpin eventual 21 CFR Part 314 or biologics licence submissions. For CMC and process development teams, the dual-indication scope means formulation and analytical method packages must accommodate two distinct patient populations from the outset.

Petrelintide, an investigational human amylin analog, produced efficacy, safety, and tolerability data from the Phase II ZUPREME-1 trial that Roche is positioning as differentiated within the weight-management class. The ongoing ZUPREME-2 study adds a type 2 diabetes arm versus placebo, mirroring the enicepatide development structure. Tolerability profile data carry particular weight for QA and regulatory leads: amylin analogs have historically presented nausea-related discontinuation challenges, and a favourable profile here directly affects label negotiations and post-market pharmacovigilance planning.

The Phase II multi-arm fixed-dose combination trial, set to initiate around mid-2026, introduces a layered CMC challenge. Fixed-dose combinations of two biologics in the GLP-1 class require independent characterisation of each active, compatibility studies, and a manufacturing process capable of meeting ICH Q10 quality system expectations across what will effectively be a novel drug product. Plant heads and supply-chain leads should note that Roche has not disclosed a manufacturing site or CDMO arrangement for the combination program; that gap will become material as Phase III enrolment timelines firm up.

A virtual investor and analyst event on 8 June 2026 will present the CT388-103 and ZUPREME-1 datasets in fuller detail, providing the first consolidated look at the evidence package Roche intends to carry into Phase III regulatory interactions.

The measurable checkpoint ahead is the mid-2026 combination trial initiation, which will confirm whether Roche's CMC and clinical operations infrastructure can sustain three concurrent late-stage obesity programs without compressing the process validation timelines each asset requires.

Source: Roche via GlobeNewswire, 1 June 2026.